Font Size: a A A
Keyword [Nilotinib]
Result: 1 - 20 | Page: 1 of 2
1. The Effects Of Nilotinib, Arsenic Trioxide On Proliferation, Apoptosis And BCR-ABL Gene Expression Of Imatinib-resistant K562 Cells
2. Synthesis Of Nilotinib
3. Individual Research Of Chronic Myelogenous Leukemia Genotyping And Observation Of Nilotinib Clinical Curative Effect
4. Preliminary Observation Of Second-generation Tyrosine Kinase Inhibitors In The Treatment Of Chronic Myelogenous Leukaemia
5. Synthesis Of5-trifluoromethyl-3-(4-methyl-1H-imidazol-1-yl)-aniline
6. The Study Of Nilotinib And Arsenic Trioxide On Differentiation Of Chronic Myeloid Leukemia K562Cells And Potential Mechanism
7. Efficacy Of Nilotinib On Imatinib-Resistant OR-Intolerant Chronic Myeloid Leukemia
8. Preliminary Observation Of Second-generation Tyrosine Kinase Inhibitors In The Treatment Of Chronic Myelogenous Leukemia
9. The Effects Of Nilotinib Combined With Arsenic Trioxide On Proliferation And Apoptosis Of K562 Cells
10. Efficacy Of Switching To Nilotinib Among Patients Failed To Achieve A BCR-ABL Transcript Level ≤10% After 6 Months After Imatinib Initiation
11. The Cytogenetic And Targeted Treatment Study Of Chronic Myeloid Leukemia
12. Study Of Clinical Treatment Of Chronic Myeloid Leukemia
13. Clinical Follow Up Of Patients Receiving Tyrosine Kinase Inhibitors For The Treatment Of Chronic Myelogenous Leukemia
14. Adverse Events Of Second-generation TKI In Newly Diagnosedchronic-phase Chronic Myeloid Leukemia(CML-CP):A Meta-analysis
15. Clinical Efficacy Of Third-Line Tyrpsine Kinase Inhibitors For Advanced Gastrointestinal Stromal Tumors After Failure Of Imatinib And Sunitinib:a Meta-Analysis
16. Efficacy Of 2nd Generation’s TKI In Treatment Of Imatinib Resistant Or Intolerant Chronic Myelogenous Leukemia
17. Application Effect Of Tyrosine Kinase Inhibitors In The Treatment Of Chronic Myeloid Leukemia
18. Effectiveness Of Nilotinib、Imatinibfor Chronic Myeloid Leukemia:a Meta-Analysis
19. Clinical Observation Of Nilotinib In Patients With Imatinib-resistant Or Intolerant Chronic Myeloid Leukemia
20. Synthesis And Process Optimization Of Nilotinib
  <<First  <Prev  Next>  Last>>  Jump to